The EU Pharma Package: Understanding the Impact on Regulatory Exclusivities in the EU.
Join us for our latest seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU.
For any medicine marketed in Europe, a key commercial consideration is the timing of generic or biosimilar market entry. Protection from competition is derived from two principal sources: intellectual property rights (patents and Supplementary Protection Certificates), and regulatory exclusivities. The new EU Pharma Package introduces changes to the regulatory exclusivities that are available.
In this seminar, Dr Andrew Wells (Partner and Head of the HGF Chemistry & Pharmaceutical Group) will explain the proposed reforms and discuss what they mean for both innovator and generic pharmaceutical companies.
We look forward to welcoming you to the seminar.
Please note photography may be taken throughout the event to be used for marketing material, if you would prefer not to be in any photographs please contact us via events@hgf.com
About the hosts:
HGF is one of Europe’s leading intellectual property firms, bringing together patent attorneys, trade mark attorneys and IP solicitors to provide a fully integrated IP solution. With offices across the UK, Ireland, the Netherlands, Germany, Switzerland, France and Austria, HGF supports innovative businesses, universities, research organisations and global brands through every stage of the IP lifecycle, from the creation and protection of intellectual property through to commercialisation, enforcement and dispute resolution. HGF is one of Europe’s largest firms of IP specialists, with IP professionals delivering seamless cross-border support to clients operating in international markets.
The firm’s multidisciplinary approach combines deep technical expertise with commercial and legal insight, enabling specialist teams across technology and engineering, life sciences, chemistry, trade marks and law to work seamlessly together to deliver strategic, business-focused advice. This collaborative model ensures clients benefit from coordinated support across patents, trade marks, designs, litigation, oppositions, appeals and commercial IP matters.